Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Perimeter Medical Imaging AI, Inc. (PINK.V)
Toronto, ON, CA
Perimeter Medical Imaging AI, Inc. is a medical technology firm focused on developing and marketing advanced imaging solutions. These innovations empower surgeons, radiologists, and pathologists to meticulously examine microscopic tissue structures directly within a clinical setting. A cornerstone offering is their optical coherence tomography (OCT) imaging system, which delivers detailed cross-sectional views of tissues to a depth of 2 millimeters, comprising the S-series OCT, B-series OCT, and an associated imaging console. Complementing this, ImgAssist, an artificial intelligence platform, streamlines image analysis. When integrated with Perimeter's OCT technology, ImgAssist becomes a robust tool, providing physicians with real-time visualization and assessment of surgical margins. This capability significantly enhances patient surgical outcomes and diminishes the necessity for subsequent operations. The company further provides a specialized image library and disposable specimen containers, catering to hospitals and cancer treatment facilities. Established in 2013, Perimeter Medical Imaging AI, Inc. operates from its headquarters in Toronto, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.55% | -7.35% | -10.00% | +5.00% | +65.79% | -10.00% | +36.96% | -81.25% | -90.25% | -26.50% | -99.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+177.0% ★ Q1'26: -31.3% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+15.8% Q1'26: +55.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-444.8% Q1'26: -582.5% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-561.6% Q1'26: -774.9% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-742.9% Q1'26: -891.8% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+15.3% Q1'26: +41.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.01× Q1'26: -0.01× (vs Q1'25)
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 52.7K (-100.0%)
|
11.3K
est: 39.5K (-71.3%)
|
132.8K
est: 537.6K (-75.3%)
|
403.5K
est: 500.8K (-19.4%)
|
846.2K
est: 840.3K (+0.7%)
|
2.34M
est: 2.49M (-6.0%)
|
6.22M
5.64M – 6.66M
+149.4% YoY
|
13.71M
11.98M – 15.05M
+120.5% YoY
|
28.76M
26.11M – 30.82M
+109.8% YoY
|
52.73M
47.86M – 56.50M
+83.3% YoY
|
97.55M
88.55M – 104.52M
+85.0% YoY
|
| EBITDA |
-6.11M
est: -31.6K (-19,203.4%)
|
-15.95M
est: -23.7K (-67,162.0%)
|
-11.72M
est: -322.6K (-3,532.7%)
|
-18.13M
est: -500.8K (-3,521.3%)
|
-12.64M
est: -840.3K (-1,403.9%)
|
-12.32M
est: -2.49M (-393.9%)
|
-6.22M
-6.66M – -5.64M
-149.4% YoY
|
-13.71M
-15.05M – -11.98M
-120.5% YoY
|
-28.76M
-30.82M – -26.11M
-109.8% YoY
|
-52.73M
-56.50M – -47.86M
-83.3% YoY
|
-97.55M
-104.52M – -88.55M
-85.0% YoY
|
| EBIT |
-10.06M
est: -31.6K (-31,698.3%)
|
-13.17M
est: -23.7K (-55,412.5%)
|
-12.76M
est: -322.6K (-3,855.9%)
|
-18.75M
est: -500.8K (-3,644.1%)
|
-13.37M
est: -840.3K (-1,490.8%)
|
-13.16M
est: -2.49M (-427.9%)
|
-6.22M
-6.66M – -5.64M
-149.4% YoY
|
-13.71M
-15.05M – -11.98M
-120.5% YoY
|
-28.76M
-30.82M – -26.11M
-109.8% YoY
|
-52.73M
-56.50M – -47.86M
-83.3% YoY
|
-97.55M
-104.52M – -88.55M
-85.0% YoY
|
| Net Income |
-8.00M
est: -10.00M (+20.0%)
|
-16.76M
est: -13.74M (-22.0%)
|
-3.59M
est: -10.85M (+67.0%)
|
-18.94M
est: -10.23M (-85.2%)
|
-13.39M
est: -15.45M (+13.3%)
|
-13.14M
est: -8.30M (-58.3%)
|
-6.34M
-6.83M – -5.50M
+23.6% YoY
|
-10.15M
-12.85M – -3.77M
-60.1% YoY
|
-13.80M
-14.65M – 1.61M
-35.9% YoY
|
5.71M
5.02M – 6.24M
+141.4% YoY
|
15.49M
13.63M – 16.93M
+171.4% YoY
|
| SGA |
8.96M
est: 12.11M (-26.0%)
|
11.56M
est: 9.08M (+27.3%)
|
10.28M
est: 123.49M (-91.7%)
|
14.68M
est: 115.32M (-87.3%)
|
12.23M
est: 193.51M (-93.7%)
|
9.19M
est: 574.15M (-98.4%)
|
1.43B
1.30B – 1.53B
+149.4% YoY
|
3.16B
2.76B – 3.47B
+120.5% YoY
|
6.62B
6.01B – 7.10B
+109.8% YoY
|
12.14B
11.02B – 13.01B
+83.3% YoY
|
22.46B
20.39B – 24.07B
+85.0% YoY
|
| EPS |
-0.29
est: -0.14 (-107.3%)
|
-0.38
est: -0.19 (-97.7%)
|
-0.06
est: -0.15 (+61.0%)
|
-0.29
est: -0.13 (-130.5%)
|
-0.19
est: -0.19 (+0.0%)
|
-0.16
est: -0.11 (-41.2%)
|
-0.08
-0.08 – -0.07
+33.1% YoY
|
-0.08
-0.16 – -0.05
-8.7% YoY
|
-0.08
-0.18 – 0.02
+4.0% YoY
|
0.07
0.06 – 0.08
+187.5% YoY
|
0.19
0.17 – 0.21
+171.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adrian Mendes | Chief Executive Officer & Director | 742.3K | male |
| Sara Brien | Chief Financial Officer | 517.7K | female |
| Abbey Goodman | Vice President of Sales | — | female |
| Stephen Kilmer | Investor Relations Officer | — | — |
| Ted James | Chief Medical Officer & Member of Advisory Board | — | — |
| Jodi Regts | Corporation Communications & Investor Relations Officer | — | female |
| Andrew Berkeley | Co-Founder & Chief Innovation Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PINK.V
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
